http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy
-
Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
-
Novartis initiates new USD 15 billion share buyback highlighting confidence in growth and pipeline
-
Novartis (NVS) Reports new Data Highlights Efficacy of Piqray in Specific Metastatic Breast Cancer
-
Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i
-
Novartis R&D day spotlights attractive growth profile, underpinned by strong in-market brands, 20 potential high value pipeline assets, and technology platforms
-
Novartis (NVS) Presents New Data Showing Kisqali Demonstrated Longest Median Overall Survival Ever in HR+/HER2- Advanced Breast Cancer
-
Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
-
Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular events
-
US Supreme Court denies Sandoz (NVS) petition to review biosimilar Erelzi case
-
US Supreme Court denies Sandoz petition to review biosimilar Erelzi® (etanercept-szzs) case
-
Cathie Wood's ARK Adds ~1.7M Shares of Twitter (TWTR), Sells Apple (AAPL), Alibaba (BABA)
-
Novartis (NVS) Granted FDA Approval for Expanded Indication for Entresto in Chronic Heart Failure
-
Novartis Entresto® granted expanded indication in chronic heart failure by FDA
-
Mesoblast Limited (MESO) Enters Global Collaboration with Novartis (NVS)
-
Novartis US Foundation commits $25M to improve health equity by reducing health disparities in the US
-
Sosei Heptares Notes That Enerzair® Breezhaler® (QVM149) has been Recommended for Approval in the European Union for Treating Uncontrolled Asthma
-
Intellia Therapeutics (NTLA) Announces FDA Accepts IND for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration
-
Novartis successfully completes acquisition of The Medicines Company, adding a potentially first-in-class, investigational cholesterol-lowering therapy inclisiran
-
Novartis completes tender offer for all outstanding shares of The Medicines Company
-
Novartis (NVS) says Kymriah demonstrated consistent efficacy and safety outcomes in US patients when used in real-world setting
-
Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
-
Novartis tender offer for The Medicines Company commences
-
Medicines Co. (MDCO) Agrees to be Acquired by Novartis AG (NVS) for $9.7B, or $85/Share
-
Amgen (AMGN) Announces it Won Patent Case on Enbrel
-
Amgen (AMGN) Novartis (NVS) & Banner Alzheimer's Institute Report Discontinuation of Clinical Research Program with BACE Inhibitor CNP520
-
8x8, Inc. (EGHT) Announces Elizabeth Theophille to Board
-
8X8, Inc. Appoints Elizabeth Theophille to Its Board of Directors
-
Long-term Survival Benefit Shown for Metastatic Melanoma Patients Treated with Novartis Tafinlar® + Mekinist®
-
Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials
-
AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)
-
Sosei Heptares Notes That a Valid Marketing Authorization Application For QVM149, a Potential New Inhaled Combination Therapy For Asthma, Has Been Filed With the European Medicines Agency
-
Verily Forms Strategic Alliances with Novartis, Otsuka, Pfizer and Sanofi to Transform Clinical Research
-
The EIU's Index of Cancer Preparedness reveals huge gaps in health system readiness and governance
-
Intellia Therapeutics (NTLA) and Novartis (NVS) Expand Cell Therapy Collaboration to Pursue CRISPR/Cas9-based Genome Editing
-
Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology
-
Pfizer Announces Clinical Development Agreement with Novartis to Advance the Treatment of NASH
-
Novartis (NVS) says analysis shows crizanlizumab increased number of patients free of sickle cell pain crises vs placebo during SUSTAIN study
-
Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study
-
Novartis (NVS) Reports Publication of Landmark PARADIGMS Study Demonstrating Significant Benefit of Gilenya
-
Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with relapsing multiple sclerosis
-
Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women
-
Novartis launches the Galaxies of Hope app, a digital experience for the Neuroendocrine Tumor (NET) cancer community
-
Novartis (NVS) Granted FDA Approval for Inclusion of New Evidence that Cosentyx (secukinumab) Inhibits Progression of Joint Structural Damage in Psoriatic Arthritis
-
Novartis receives FDA approval for inclusion of new evidence that Cosentyx® inhibits progression of joint structural damage in psoriatic arthritis
-
Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life
-
Novartis (NVS) Says FDA Expedited Review of its drug Promacta for first-line SAA
-
FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)
-
Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer
-
Novartis successfully completes acquisition of AveXis, Inc.
